Arrowstreet Capital’s AC Immune ACIU Stock Holding History

Arrowstreet Capital’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12M	Buy	405,658 +30,035	+8%	+$93.3K	﹤0.01%	1535
2025 Q4	$1.18M	Buy	+375,623	New	+$1.18M	﹤0.01%	1519
2021 Q4	–	Sell	-47,715	Closed	-$320K	–	1415
2021 Q3	$320K	Hold	47,715	–	–	﹤0.01%	1466
2021 Q2	$378K	Sell	47,715 -80,383	-63%	-$556K	﹤0.01%	1719
2021 Q1	$975K	Buy	128,098 +1,391	+1%	+$9.93K	﹤0.01%	1797
2020 Q4	$655K	Sell	126,707 -75,212	-37%	-$384K	﹤0.01%	1948
2020 Q3	$985K	Buy	201,919 +600	+0.3%	+$4.31K	﹤0.01%	1819
2020 Q2	$1.35M	Hold	201,319	–	–	﹤0.01%	1652
2020 Q1	$1.39M	Buy	201,319 +185,919	+1,207%	+$1.45M	﹤0.01%	1196
2019 Q4	$131K	Buy	+15,400	New	+$103K	﹤0.01%	1651
2018 Q4	–	Sell	-21,644	Closed	-$173K	–	1322
2018 Q3	$173K	Buy	+21,644	New	+$218K	﹤0.01%	1029

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Arrowstreet Capital's ACIU Position: Q1 2026 in Review

Arrowstreet Capital increased its AC Immune (ACIU) stake by 8% in Q1 2026, buying an estimated $93.3K and bringing the position to 405,658 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Arrowstreet Capital first reported a position in ACIU in Q3 2018 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2020. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.

Arrowstreet Capital held 405,658 shares of AC Immune worth $1.12M as of Q1 2026.
Arrowstreet Capital bought 30,035 AC Immune shares in Q1 2026, an estimated $93.3K.
AC Immune made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1535 holding.
Arrowstreet Capital first reported a position in AC Immune in Q3 2018 and has held it in 11 quarters since.
Arrowstreet Capital's AC Immune position peaked at $1.39M in Q1 2020.
46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.